KCNJ11 and congenital isolated hyperinsulinism: The main treatment for CHI is the KATP channel‐opener diazoxide; however, patients with ABCC8/KCNJ11 mutations that prevent trafficking to the membrane do not respond to the drug as diazoxide targets the SUR1 subunit of the KATP channel.